Witnessing the stock’s movement on the chart, on Wednesday, Stoke Therapeutics Inc (NASDAQ: STOK) had a quiet start as it plunged -0.25% to $31.74, before settling in for the price of $31.82 at the close. Taking a more long-term approach, STOK posted a 52-week range of $5.35-$38.69.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 1.74%. Meanwhile, its Annual Earning per share during the time was 1.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 109.70%. This publicly-traded company’s shares outstanding now amounts to $55.12 million, simultaneously with a float of $46.32 million. The organization now has a market capitalization sitting at $1.81 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.04, while the 200-day Moving Average is $18.44.
Stoke Therapeutics Inc (STOK) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Stoke Therapeutics Inc’s current insider ownership accounts for 18.91%, in contrast to 104.10% institutional ownership. According to the most recent insider trade that took place on Dec 08 ’25, this organization’s GENERAL COUNSEL & CORP SEC sold 3,978 shares at the rate of 32.28, making the entire transaction reach 128,411 in total value, affecting insider ownership by 11,831. Preceding that transaction, on Dec 08 ’25, Company’s Director sold 13,430 for 32.27, making the whole transaction’s value amount to 433,385. This particular insider is now the holder of 49,124 in total.
Stoke Therapeutics Inc (STOK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year. Stoke Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 109.70% and is forecasted to reach -3.06 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -14.26% through the next 5 years, which can be compared against the 1.74% growth it accomplished over the previous five years trading on the market.
Stoke Therapeutics Inc (NASDAQ: STOK) Trading Performance Indicators
Let’s observe the current performance indicators for Stoke Therapeutics Inc (STOK). It’s Quick Ratio in the last reported quarter now stands at 6.53. Alongside those numbers, its PE Ratio stands at $48.10, and its Beta score is 1.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.82. Similarly, its price to free cash flow for trailing twelve months is now 34.62.
In the same vein, STOK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.66, a figure that is expected to reach -0.71 in the next quarter, and analysts are predicting that it will be -3.06 at the market close of one year from today.
Technical Analysis of Stoke Therapeutics Inc (STOK)
Going through the that latest performance of [Stoke Therapeutics Inc, STOK]. Its last 5-days volume of 0.41 million was inferior to the volume of 0.91 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 30.36% While, its Average True Range was 48.60.
Raw Stochastic average of Stoke Therapeutics Inc (STOK) in the period of the previous 100 days is set at 73.08%, which indicates a major rise in contrast to 16.70% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.67 that was lower than 1.81 volatility it exhibited in the past 100-days period.
